12:00 AM
 | 
Nov 05, 2001
 |  BioCentury  |  Tools & Techniques

ACE in the hole

Companies obviously benefit by expanding the indications for their drugs. What drives this process isn't always obvious, however.

As it sometimes turns out, testing of new indications may be driven as often by the need of clinicians for new treatments as it is by a corporate desire for more sales. In the case of supplementary indications for angiotension-II receptor antagonists (AIIRAs), originally marketed to treat hypertension, it appears that pharma companies followed the lead of physicians and basic research scientists who were intent on treating patients with chronic nephropathy.

Researchers last week published in the Proceedings of the National Academy of Sciences that mice with increased copy numbers of an angiotensin-1 converting enzyme (ACE) had a corresponding increase in serum ACE levels up to 162% those of wild type mice. Mice with three ACE copies showed increased nephropathy after induction of diabetes as...

Read the full 696 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >